Skip to main content
Caplight Logo









KaliVir Immunotherapeutics

KaliVir Immunotherapeutics

Private
Pittsburgh, PennsylvaniaHealthcare & Life Scienceshttps://kalivir.com/

Last Round

Series A

Extension

Aug 19, 2026

Total Funding Raised

$29M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

KaliVir Immunotherapeutics is a biotechnology company developing next-generation oncolytic viral immunotherapy programs for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncolytic virusoncolytic immunotherapyVET platformsolid tumor therapycancer immunotherapyvaccinia virusbiotech licensingcold to hot tumortumor lysisviral therapyonco-virologydrug discoveryprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KaliVir Immunotherapeutics Comparables

Compare KaliVir Immunotherapeutics with similar companies based on industry and business-model similarity.

KaliVir Immunotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Accession Therapeutics Limited
87%
Virogin Biotech
86%
TILT Biotherapeutics
85%

KaliVir Immunotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionAug 19, 2026
Series AMar 16, 2022

Key People

Founding team and executive leadership

Helena Chaye

Chief Executive Officer

Executive Team

KaliVir Immunotherapeutics Investors

Notable investors and investment history

KaliVir Immunotherapeutics investors
InvestorRounds
SV InvestmentSeries A Extension
Premier PartnersSeries A
NextransSeries A Extension
QUAD Investment ManagementSeries A Extension, Series A
Company K PartnersSeries A, Series A Extension
Company K PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 19, 2026

    $14M round with participation from QUAD Investment Management and SV Investment.

  • Jan 23, 2026

    Monthly visitors grew 95% MoM, reaching 1.6K.

Recent news

Latest coverage and updates

  • receives_financingAug 19, 2026

    KaliVir Immunotherapeutics, Inc. received financing of $14M in Series A1 on Aug 19th '26.

KaliVir Immunotherapeutics Filings

Explore SEC and related filing metadata, where available.

KaliVir Immunotherapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about KaliVir Immunotherapeutics's valuation, stock price, and market status.

Is KaliVir Immunotherapeutics a public or private company?

KaliVir Immunotherapeutics is a private company.

What is the current stock price of KaliVir Immunotherapeutics?

KaliVir Immunotherapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is KaliVir Immunotherapeutics worth (valuation)?

Valuation information for KaliVir Immunotherapeutics is not publicly available.

Can I buy KaliVir Immunotherapeutics stock?

KaliVir Immunotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was KaliVir Immunotherapeutics's last funding round?

KaliVir Immunotherapeutics's most recent funding round was Series A on March 16, 2022.

Who are the main investors in KaliVir Immunotherapeutics?

Key investors in KaliVir Immunotherapeutics include Premier Partners.

Will KaliVir Immunotherapeutics IPO soon?

No public IPO plans have been announced for KaliVir Immunotherapeutics.

How can I track KaliVir Immunotherapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor KaliVir Immunotherapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPittsburgh, Pennsylvania
Employee Range23
Year Founded2019
Last FundingAug 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?